Strategies to Overcome Endocrine Therapy Resistance in HR+/HER2-negative Breast Cancer
TeleECHO Series


Questions marked with a * are required
Contact Information
Which of the following interventions is NOT part of a plan to support a patient’s consistent, chronic, and tolerable use of oral anti-cancer medications for HR-positive/ HER2-negative breast cancer? 
A 52-year-old woman with HR-positive/HER2-negative early breast cancer is starting abemaciclib as part of an adjuvant therapy regimen. Which of the following adverse events is most commonly associated with abemaciclib?
Mrs. Smith is a 55-year-old patient with HR-positive/HER2-negative early breast cancer who is considering taking an oral anti-cancer medication. She is concerned about the potential side effects of the medication but also eager to do everything she can to reduce her risk of recurrence. Which of the following is the BEST shared decision-making strategy that the healthcare provider could use to support her adherence and persistence with the oral anti-cancer medication?
Powered by QuestionPro